In this review, we discuss the most important recent developments in the biosimilars space, including new biosimilar approvals and launches, litigation under the Biologics Price.
Amgen opens its most advanced manufacturing facility to date europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Johnson & Johnson on Tuesday
reported fourth-quarter profit above Wall Street expectations,
helped by demand for its blockbuster psoriasis treatment Stelara
and strength in its medical device unit. .
(Reuters) -Johnson & Johnson on Tuesday reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psoriasis drug Stelara, which is expected to face fresh U.S. competition from biosimilar versions next year. A key patent for Stelara expired in the United States last year, but J&J struck deals with competitors to delay the launches of their biosimilars until 2025. Analysts have said the delay in biosimilar launches would make Stelara a larger contributor to J&J's 2024 and 2025 sales than previously anticipated.
Earlier this year, the U.S. Food and Drug Administration announced approval of Amgen's Wezlana (ustekinumab-auub) as an interchangeable biosimilar to Janssen Biotech's Stelara.